LSI Europe

At LSI Europe ’25, one of the more revealing conversations was not about a single therapeutic area, product category, or financing milestone. It was about portfolio construction itself. In a debate session titled “Including Medtech, Biotech, or Healthtech in Your VC Thesis,” investors from TVM Capital Life Science, Canaan Partners, Santé Ventures, Brightlands Venture Partners, and Unorthodox Ventures offered a candid look at how they think about risk, timing, capital efficiency, and long-term returns across healthcare. For founders trying to understand what different investors actually want, the discussion provided a sharp window into how medtech venture capital firms are making decisions in a more disciplined market. Moderated by Luc Marengere of TVM Capital Life Science, the panel made one thing clear early: there is no single right way to build a healthcare investment strategy. Some firms continue to back medtech as a core pillar. Others have stepped away from it at the earliest sta...

And while verbal yeses may feel like validation, they’re not always equal. “ICs [investment committees] will have different thresholds,” Masterson added. “You can end up in a chicken-and-egg scenario, needing to herd a full syndicate into alignment just to move forward.” Post-term sheet diligence is when the real work begins. For entrepreneurs, it’s about managing momentum while under a microscope. For medtech investors, it’s about confirming the deal’s risk profile—beyond the pitch deck. Visit here: https://www.flipgorilla.com/p/29362908924217984/show

Unlike a traditional trade show, LSI Summits are hosted in world-class venues — creating a productive experience that senior executives look forward to year after year. 200 early and growth-stage companies took the stage at LSI Europe ‘25 in London, representing Europe, the United States, APAC, and more. Visit here: https://www.lsieuropesummit.com/